Clinical trial NCT00354640: Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
Official title: A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: breast cancer
breast cancer in situ
ductal breast carcinoma in situ
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2006-07-20
Enrollment: 11
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive breast cancer, ductal carcinoma in situ, or a high risk of breast cancer.

PURPOSE: This phase II trial is studying how well giving simvastatin together with anastrozole works in treating postmenopausal women with invasive breast cancer, ductal carcinoma in situ, or a high risk of breast cancer.

Detailed description: OBJECTIVES:

Primary

* Assess the effects of concurrent anastrozole and simvastatin on anastrozole's steady-state concentration in postmenopausal women with history of invasive breast cancer or ductal carcinoma in situ or at high risk for developing breast cancer.

Secondary

* Study the effect of concurrent simvastatin and anastrozole on estrogen suppression in these patients.

OUTLINE: This is a pilot study.

Patients continue to receive oral anastrozole once daily (as prior to study entry). They also receive oral simvastatin once daily for 14-18 days in the absence of unacceptable toxicity or diagnosis of new or recurrent breast cancer.

Patients undergo blood sample collection at baseline and after study therapy for analysis of anastrozole and hormone (estradiol and estrogen) concentrations.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Meets any of the following criteria:

  * History of invasive breast cancer
  * History of ductal carcinoma in situ
  * At high risk for breast cancer, defined as being on anastrozole for chemoprevention of breast cancer
* Receiving anastrozole for ≥ 30 days as adjuvant breast cancer treatment or for prevention of breast cancer
* No active breast cancer with known metastatic involvement
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Female
* Postmenopausal
* ECOG performance status 0-2
* AST and ALT ≤ 3 times upper limit of normal
* Creatinine clearance ≥ 30 mL/min
* No active liver disease
* No prior hypersensitivity to any HMG-CoA reductase inhibitor or any of its components
* No daily alcohol use of \> 3 standard drinks/day

  * A standard drink is defined as 10 g of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No cholesterol-lowering drug, including a statin, within the past 3 months
* No selective estrogen receptor modulator (SERM) within the past 3 months
* No other hormone therapy within the past 3 months
* No prior estrogen and/or progesterone hormone replacement therapy that lasted for ≥ 5 years

  * Vaginal estrogen preparations allowed
* No other concurrent statin or cholesterol-lowering drug
* No other concurrent SERM
* No other concurrent hormone therapy
* No other concurrent investigational drugs
* No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or cyclosporine
* No concurrent chemotherapy or biological agents
* No concurrent daily grapefruit juice \> 8 oz/day
* No other concurrent anticancer agents or therapies

Primary outcomes:
measure: Change in Blood Concentrations
timeFrame: Baseline and 14 days
Secondary outcomes:
measure: Change in Serum Estradiol Levels
timeFrame: Baseline and 14 days
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
state: Maryland
Study officials:
affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
name: Vered Stearns, MD
role: PRINCIPAL_INVESTIGATOR
References: